Shares of NGM Biopharmaceuticals (NASDAQ:NGM) are tanking today after the topline results from its Phase 2 study of NGM621 for the treatment of geographic atrophy  (GA) secondary to age-related macular degeneration (AMD) showed that the drug failed to meet the primary endpoints. Further details and findings from this study are anticipated in November at the Retina Society annual meeting.
https://www.tipranks.com/news/ngm-bio-tanks-after-ngm621-fails-in-phase-2-study?utm_source=advfn.com&utm_medium=referral
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From May 2023 to Jun 2023 Click Here for more NGM Biopharmaceuticals Charts.
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Jun 2022 to Jun 2023 Click Here for more NGM Biopharmaceuticals Charts.